Print Page     Close Window     

SEC Filings

SERES THERAPEUTICS, INC. filed this Form 8-K on 10/16/2017
Entire Document

Slide 8

SER-287 Phase 1b study endpoints Primary Objectives Safety and tolerability Change in composition of intestinal microbiome at 8 weeks * Secondary Objectives Clinical remission, endoscopic improvement, and response through measure of the total modified Mayo Score Change in serum and fecal biomarkers * Complement of microbiome metabolic pathways from stool, urine and blood * Immunological and pathologic changes in mucosal biopsies * * Microbiome data and other biomarker data are expected in the coming months

© Seres Therapeutics. All Rights Reserved.